Which has higher valuation and earnings, NEO or CHE?

Chemed has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $766.30M 2.77 -$108.03M -$0.40 N/A Chemed $2.53B 2.84 $265.24M $19.91 27.57

Is NEO or CHE more profitable?

Chemed has a net margin of 10.60% compared to NeoGenomics' net margin of -6.77%. Chemed's return on equity of 31.77% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -6.77% -1.99% -1.21% Chemed 10.60% 31.77% 18.90%

Does the media refer more to NEO or CHE?

In the previous week, Chemed had 6 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for Chemed and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat Chemed's score of 0.73 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NEO or HIMS?

In the previous week, Hims & Hers Health had 14 more articles in the media than NeoGenomics. MarketBeat recorded 21 mentions for Hims & Hers Health and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat Hims & Hers Health's score of 0.39 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 6 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NEO or BLLN?

In the previous week, Billiontoone had 22 more articles in the media than NeoGenomics. MarketBeat recorded 29 mentions for Billiontoone and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat Billiontoone's score of 0.21 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Billiontoone 8 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, NEO or HNGE?

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $766.30M 2.77 -$108.03M -$0.40 N/A Hinge Health $587.86M 12.08 -$528.26M $1.28 71.72

Is NEO or HNGE more profitable?

Hinge Health has a net margin of 15.15% compared to NeoGenomics' net margin of -6.77%. Hinge Health's return on equity of 65.44% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -6.77% -1.99% -1.21% Hinge Health 15.15% 65.44% 14.54%

Does the media prefer NEO or HNGE?

In the previous week, Hinge Health had 19 more articles in the media than NeoGenomics. MarketBeat recorded 26 mentions for Hinge Health and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat Hinge Health's score of 0.61 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hinge Health 5 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, NEO or RDNT?

RadNet has higher revenue and earnings than NeoGenomics. RadNet is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $766.30M 2.77 -$108.03M -$0.40 N/A RadNet $2.04B 2.97 -$18.65M -$0.18 N/A

Is NEO or RDNT more profitable?

RadNet has a net margin of -0.66% compared to NeoGenomics' net margin of -6.77%. RadNet's return on equity of 2.77% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -6.77% -1.99% -1.21% RadNet -0.66% 2.77% 0.97%

Does the media refer more to NEO or RDNT?

In the previous week, RadNet had 7 more articles in the media than NeoGenomics. MarketBeat recorded 14 mentions for RadNet and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat RadNet's score of 1.04 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RadNet 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

NeoGenomics (NEO) Competitors

$16.54 -0.03 (-0.18%)

As of 03:05 PM Eastern

Compare

NEO vs. CHE, HIMS, BLLN, HNGE, and RDNT

Should you buy NeoGenomics stock or one of its competitors? MarketBeat compares NeoGenomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeoGenomics include Chemed (CHE), Hims & Hers Health (HIMS), Billiontoone (BLLN), Hinge Health (HNGE), and RadNet (RDNT). These companies are all part of the "healthcare services" industry.

How does NeoGenomics compare to Chemed?

NeoGenomics (NASDAQ:NEO) and Chemed (NYSE:CHE) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Chemed has a net margin of 10.60% compared to NeoGenomics' net margin of -6.77%. Chemed's return on equity of 31.77% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Chemed	10.60%	31.77%	18.90%

Chemed has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$766.30M	2.77	-$108.03M	-$0.40	N/A
Chemed	$2.53B	2.84	$265.24M	$19.91	27.57

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Comparatively, 3.3% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

NeoGenomics presently has a consensus price target of $16.71, indicating a potential upside of 1.05%. Chemed has a consensus price target of $530.75, indicating a potential downside of 3.32%. Given NeoGenomics' stronger consensus rating and higher probable upside, equities research analysts clearly believe NeoGenomics is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Chemed had 6 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for Chemed and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat Chemed's score of 0.73 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeoGenomics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Summary

Chemed beats NeoGenomics on 10 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to Hims & Hers Health?

NeoGenomics (NASDAQ:NEO) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Hims & Hers Health had 14 more articles in the media than NeoGenomics. MarketBeat recorded 21 mentions for Hims & Hers Health and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat Hims & Hers Health's score of 0.39 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	6 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeoGenomics currently has a consensus target price of $16.71, indicating a potential upside of 1.05%. Hims & Hers Health has a consensus target price of $31.43, indicating a potential downside of 1.31%. Given NeoGenomics' stronger consensus rating and higher possible upside, research analysts plainly believe NeoGenomics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Hims & Hers Health has a net margin of -0.56% compared to NeoGenomics' net margin of -6.77%. Hims & Hers Health's return on equity of 6.10% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Hims & Hers Health	-0.56%	6.10%	1.52%

NeoGenomics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market.

Hims & Hers Health has higher revenue and earnings than NeoGenomics. Hims & Hers Health is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$766.30M	2.77	-$108.03M	-$0.40	N/A
Hims & Hers Health	$2.35B	3.14	$128.37M	-$0.09	N/A

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 1.1% of NeoGenomics shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Hims & Hers Health beats NeoGenomics on 10 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to Billiontoone?

NeoGenomics (NASDAQ:NEO) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Billiontoone has a net margin of 8.04% compared to NeoGenomics' net margin of -6.77%. Billiontoone's return on equity of 9.96% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Billiontoone	8.04%	9.96%	5.35%

Billiontoone has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$766.30M	2.77	-$108.03M	-$0.40	N/A
Billiontoone	$305.11M	14.75	$7.45M	$0.70	139.75

In the previous week, Billiontoone had 22 more articles in the media than NeoGenomics. MarketBeat recorded 29 mentions for Billiontoone and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat Billiontoone's score of 0.21 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	8 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.5% of NeoGenomics shares are owned by institutional investors. 1.1% of NeoGenomics shares are owned by insiders. Comparatively, 50.2% of Billiontoone shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NeoGenomics presently has a consensus target price of $16.71, suggesting a potential upside of 1.05%. Billiontoone has a consensus target price of $126.71, suggesting a potential upside of 29.53%. Given Billiontoone's higher possible upside, analysts plainly believe Billiontoone is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Billiontoone beats NeoGenomics on 10 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Hinge Health?

NeoGenomics (NASDAQ:NEO) and Hinge Health (NYSE:HNGE) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

NeoGenomics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Hinge Health has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

98.5% of NeoGenomics shares are held by institutional investors. 1.1% of NeoGenomics shares are held by company insiders. Comparatively, 18.9% of Hinge Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Hinge Health has a net margin of 15.15% compared to NeoGenomics' net margin of -6.77%. Hinge Health's return on equity of 65.44% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Hinge Health	15.15%	65.44%	14.54%

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$766.30M	2.77	-$108.03M	-$0.40	N/A
Hinge Health	$587.86M	12.08	-$528.26M	$1.28	71.72

NeoGenomics currently has a consensus price target of $16.71, suggesting a potential upside of 1.05%. Hinge Health has a consensus price target of $100.57, suggesting a potential upside of 9.56%. Given Hinge Health's stronger consensus rating and higher probable upside, analysts clearly believe Hinge Health is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Hinge Health	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Hinge Health had 19 more articles in the media than NeoGenomics. MarketBeat recorded 26 mentions for Hinge Health and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat Hinge Health's score of 0.61 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hinge Health	5 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Hinge Health beats NeoGenomics on 12 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to RadNet?

NeoGenomics (NASDAQ:NEO) and RadNet (NASDAQ:RDNT) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

NeoGenomics currently has a consensus target price of $16.71, indicating a potential upside of 1.05%. RadNet has a consensus target price of $87.43, indicating a potential upside of 13.27%. Given RadNet's stronger consensus rating and higher probable upside, analysts clearly believe RadNet is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
RadNet	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.80

RadNet has a net margin of -0.66% compared to NeoGenomics' net margin of -6.77%. RadNet's return on equity of 2.77% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
RadNet	-0.66%	2.77%	0.97%

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 1.1% of NeoGenomics shares are held by insiders. Comparatively, 5.1% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, RadNet had 7 more articles in the media than NeoGenomics. MarketBeat recorded 14 mentions for RadNet and 7 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.43 beat RadNet's score of 1.04 indicating that NeoGenomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RadNet	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

RadNet has higher revenue and earnings than NeoGenomics. RadNet is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$766.30M	2.77	-$108.03M	-$0.40	N/A
RadNet	$2.04B	2.97	-$18.65M	-$0.18	N/A

NeoGenomics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, RadNet has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Summary

RadNet beats NeoGenomics on 12 of the 17 factors compared between the two stocks.

Get NeoGenomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEO vs. The Competition

Export

Metric	NeoGenomics	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.12B	$9.98B	$7.04B	$12.94B
Dividend Yield	N/A	2.55%	2.58%	10.20%
P/E Ratio	-41.35	25.69	269.98	24.78
Price / Sales	2.77	4.85	651.07	108.19
Price / Cash	49.46	25.58	28.89	37.44
Price / Book	2.56	5.37	11.26	6.43
Net Income	-$108.03M	$309.96M	$3.45B	$347.27M
7 Day Performance	4.42%	1.10%	3.50%	2.54%
1 Month Performance	17.22%	0.51%	-0.64%	-1.00%
1 Year Performance	185.17%	23.64%	77.23%	23.33%

NeoGenomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEO NeoGenomics	1.7726 of 5 stars	$16.54 -0.2%	$16.71 +1.1%	+185.7%	$2.12B	$766.30M	N/A	2,500	Positive News
CHE Chemed	3.805 of 5 stars	$540.89 +1.6%	$530.75 -1.9%	+26.7%	$7.07B	$2.53B	27.17	15,811	Dividend Increase
HIMS Hims & Hers Health	2.0866 of 5 stars	$30.85 +11.1%	$31.43 +1.9%	-39.1%	$6.43B	$2.35B	N/A	2,442
BLLN Billiontoone	4.4052 of 5 stars	$137.32 -0.9%	$126.00 -8.2%	N/A	$6.37B	$305.11M	249.67	620	Earnings Report Analyst Downgrade
HNGE Hinge Health	4.2442 of 5 stars	$77.61 +3.9%	$86.07 +10.9%	+56.5%	$5.78B	$587.86M	N/A	1,437	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEO) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Competitors

NEO vs. CHE, HIMS, BLLN, HNGE, and RDNT

How does NeoGenomics compare to Chemed?

Summary

How does NeoGenomics compare to Hims & Hers Health?

Summary

How does NeoGenomics compare to Billiontoone?

Summary

How does NeoGenomics compare to Hinge Health?

Summary

How does NeoGenomics compare to RadNet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeoGenomics (NEO) Competitors

NEO vs. CHE, HIMS, BLLN, HNGE, and RDNT

How does NeoGenomics compare to Chemed?

Is NEO or CHE more profitable?

Which has higher valuation and earnings, NEO or CHE?

Do insiders and institutionals hold more shares of NEO or CHE?

Do analysts rate NEO or CHE?

Does the media refer more to NEO or CHE?

Which has more risk and volatility, NEO or CHE?

Summary

How does NeoGenomics compare to Hims & Hers Health?

Does the media refer more to NEO or HIMS?

Do analysts rate NEO or HIMS?

Is NEO or HIMS more profitable?

Which has more risk & volatility, NEO or HIMS?

Which has stronger earnings & valuation, NEO or HIMS?

Do institutionals & insiders hold more shares of NEO or HIMS?

Summary

How does NeoGenomics compare to Billiontoone?

Is NEO or BLLN more profitable?

Which has better earnings & valuation, NEO or BLLN?

Does the media favor NEO or BLLN?

Do insiders and institutionals have more ownership in NEO or BLLN?

Do analysts rate NEO or BLLN?

Summary

How does NeoGenomics compare to Hinge Health?

Which has more volatility and risk, NEO or HNGE?

Do institutionals & insiders have more ownership in NEO or HNGE?

Is NEO or HNGE more profitable?

Which has higher valuation & earnings, NEO or HNGE?

Do analysts recommend NEO or HNGE?

Does the media prefer NEO or HNGE?

Summary

How does NeoGenomics compare to RadNet?

Do analysts recommend NEO or RDNT?

Is NEO or RDNT more profitable?

Do institutionals and insiders believe in NEO or RDNT?

Does the media refer more to NEO or RDNT?

Which has higher earnings and valuation, NEO or RDNT?

Which has more volatility & risk, NEO or RDNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools